Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Total Current Liabilities of $143.5 million for Q1 2026, up 66.27% year-over-year from $86.3 million in Q1 2025, and up 5.76% quarter-over-quarter from $135.7 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $143.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 66.27% year-over-year to $143.5 million; the TTM figure through Mar 2026 stood at $143.5 million (up 66.27% YoY), while the FY2025 annual figure was $135.7 million, up 68.33% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $143.5 million, up from $135.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $143.5 million in Q1 2026, with the low at $11.7 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $42.5 million (2024), against an average of $56.2 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities increased 5.11% in 2023, then surged 249.28% in 2024.
- Tarsus Pharmaceuticals' Total Current Liabilities stood at $15.4 million in 2022, then jumped by 139.39% to $36.9 million in 2023, then surged by 118.25% to $80.6 million in 2024, then soared by 68.33% to $135.7 million in 2025, then increased by 5.76% to $143.5 million in 2026.
- Business Quant data shows TARS's Total Current Liabilities at $143.5 million in Q1 2026, $135.7 million in Q4 2025, and $117.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 175.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 175.75 Mn |
| Mar 31, 2026 | 143.51 Mn |
| Dec 31, 2025 | 135.70 Mn |
| Sep 30, 2025 | 117.05 Mn |
| Jun 30, 2025 | 90.25 Mn |
| Mar 31, 2025 | 86.31 Mn |
| Dec 31, 2024 | 80.61 Mn |
| Sep 30, 2024 | 65.87 Mn |
| Jun 30, 2024 | 51.57 Mn |
| Mar 31, 2024 | 42.53 Mn |
| Dec 31, 2023 | 36.94 Mn |
| Sep 30, 2023 | 23.25 Mn |
| Jun 30, 2023 | 14.77 Mn |
| Mar 31, 2023 | 13.26 Mn |
| Dec 31, 2022 | 15.43 Mn |
| Sep 30, 2022 | 14.27 Mn |
| Jun 30, 2022 | 11.72 Mn |
| Mar 31, 2022 | 12.61 Mn |
| Dec 31, 2021 | 11.48 Mn |
| Sep 30, 2021 | 10.37 Mn |